Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 46.4% in March

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 4,500 shares, a drop of 46.4% from the February 28th total of 8,400 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 7,100 shares, the short-interest ratio is presently 0.6 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, March 20th.

Xenetic Biosciences Price Performance

XBIO stock opened at $3.12 on Friday. The firm has a market cap of $4.81 million, a price-to-earnings ratio of -1.17 and a beta of 2.17. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.20. The firm has a fifty day moving average price of $3.89 and a two-hundred day moving average price of $3.97.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. As a group, analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Institutional Trading of Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. LGT Group Foundation acquired a new position in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned about 0.71% of Xenetic Biosciences at the end of the most recent reporting period. 15.12% of the stock is currently owned by hedge funds and other institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.